Norges Bank Makes New $7.96 Million Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Norges Bank purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNFree Report) in the 4th quarter, Holdings Channel reports. The institutional investor purchased 275,140 shares of the specialty pharmaceutical company’s stock, valued at approximately $7,963,000.

Other large investors also recently modified their holdings of the company. Quadrant Capital Group LLC increased its holdings in shares of Supernus Pharmaceuticals by 1,117.6% in the fourth quarter. Quadrant Capital Group LLC now owns 1,449 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 1,330 shares in the last quarter. Covestor Ltd increased its holdings in shares of Supernus Pharmaceuticals by 115.0% in the third quarter. Covestor Ltd now owns 2,350 shares of the specialty pharmaceutical company’s stock worth $65,000 after acquiring an additional 1,257 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Supernus Pharmaceuticals by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,314 shares of the specialty pharmaceutical company’s stock worth $183,000 after buying an additional 4,913 shares during the period. Envestnet Portfolio Solutions Inc. acquired a new position in shares of Supernus Pharmaceuticals during the third quarter worth about $262,000. Finally, Profund Advisors LLC boosted its position in shares of Supernus Pharmaceuticals by 17.7% during the third quarter. Profund Advisors LLC now owns 9,660 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 1,454 shares during the period.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $27.15 on Friday. The stock has a market capitalization of $1.49 billion, a P/E ratio of -93.62 and a beta of 0.93. The business has a 50-day moving average of $29.78 and a 200-day moving average of $29.33. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $21.99 and a fifty-two week high of $35.96.

Analyst Upgrades and Downgrades

Separately, Piper Sandler reduced their price objective on Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating for the company in a research report on Wednesday, February 28th.

Get Our Latest Report on SUPN

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 12,364 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $35.31, for a total transaction of $436,572.84. Following the completion of the transaction, the vice president now directly owns 8,570 shares of the company’s stock, valued at $302,606.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Padmanabh P. Bhatt sold 12,364 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $35.31, for a total transaction of $436,572.84. Following the completion of the transaction, the vice president now directly owns 8,570 shares of the company’s stock, valued at $302,606.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Padmanabh P. Bhatt sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $32.99, for a total value of $128,133.16. Following the transaction, the vice president now directly owns 8,570 shares of the company’s stock, valued at $282,724.30. The disclosure for this sale can be found here. Insiders sold 30,739 shares of company stock valued at $1,076,383 over the last three months. Company insiders own 8.76% of the company’s stock.

About Supernus Pharmaceuticals

(Free Report)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Recommended Stories

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNFree Report).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.